| Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone G Chakrabarti, ZR Moore, X Luo, M Ilcheva, A Ali, M Padanad, Y Zhou, ... Cancer & metabolism 3 (1), 12, 2015 | 196 | 2015 |
| Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly (ADP-ribose) polymerase inhibitors X Huang, EA Motea, ZR Moore, J Yao, Y Dong, G Chakrabarti, JA Kilgore, ... Cancer cell 30 (6), 940-952, 2016 | 138 | 2016 |
| NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone Z Moore, G Chakrabarti, X Luo, A Ali, Z Hu, FJ Fattah, R Vemireddy, ... Cell death & disease 6 (1), e1599-e1599, 2015 | 100 | 2015 |
| What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up A Buteau, CA Seideman, RS Svatek, RF Youssef, G Chakrabarti, G Reed, ... Urologic Oncology: Seminars and Original Investigations 32 (2), 128-134, 2014 | 77 | 2014 |
| Depleting tumor-NQO1 potentiates anoikis and inhibits growth of NSCLC B Madajewski, MA Boatman, G Chakrabarti, DA Boothman, EA Bey Molecular Cancer Research 14 (1), 14-25, 2016 | 75 | 2016 |
| Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone G Chakrabarti, MA Silvers, M Ilcheva, Y Liu, ZR Moore, X Luo, J Gao, ... Scientific reports 5 (1), 17066, 2015 | 71 | 2015 |
| Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer G Chakrabarti Radiation oncology 10 (1), 145, 2015 | 65 | 2015 |
| NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer LS Li, S Reddy, ZH Lin, S Liu, H Park, SG Chun, WG Bornmann, ... Molecular cancer therapeutics 15 (7), 1757-1767, 2016 | 61 | 2016 |
| Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers L Cao, LS Li, C Spruell, L Xiao, G Chakrabarti, EA Bey, KE Reinicke, ... Antioxidants & redox signaling 21 (2), 237-250, 2014 | 51 | 2014 |
| Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways G Chakrabarti, DE Gerber, DA Boothman Clinical pharmacology: Advances and Applications, 57-68, 2015 | 24 | 2015 |
| Late-Stage Sulfoximination: Improved Synthesis of the Anticancer Drug Candidate Atuveciclib T Glachet, X Franck, V Reboul Synthesis 51 (04), 971-975, 2019 | 18 | 2019 |
| Using DNA devices to track anticancer drug activity D Kahanda, G Chakrabarti, MA Mcwilliams, DA Boothman, JD Slinker Biosensors and Bioelectronics 80, 647-653, 2016 | 15 | 2016 |
| Hydrogen peroxide inhibition of bicupin oxalate oxidase JM Goodwin, H Rana, J Ndungu, G Chakrabarti, EW Moomaw Plos one 12 (5), e0177164, 2017 | 5 | 2017 |
| Tumor-specific targeting of the NAD metabolome with β-lapachone and NamPT inhibition Z Moore, DA Boothman Cancer Research 74 (19_Supplement), 1760-1760, 2014 | 2 | 2014 |
| Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology R Schnaar, JC Paulson, MS Macauley, C Nycholat, F Pfrengle, ... Glycobiology 22 (11), 1518, 2012 | 2 | 2012 |
| Compositions and methods for production of value-added chemicals TM Lee, BF Fisher, P Wiemann, G Chakrabarti, P Nguyen, K Loftis, S Qian, ... US Patent App. 18/580,308, 2024 | 1 | 2024 |
| Compositions and methods for production of glucose oxidation products TM Lee, S Qian, BF Fisher, S Downing, G Chakrabarti, S Hunt US Patent App. 17/905,736, 2023 | 1 | 2023 |
| Novel Oxidized Sugar Compounds: A Cheap, Low Dose, Environmentally Friendly, Replacement for Triazine P Schuber, JS An, C Arceo, T Lee, J Helander, T Swanson, K Huddleston, ... SPE/AAPG/SEG Unconventional Resources Technology Conference, D033S064R004, 2020 | 1 | 2020 |
| Inhibiting KRAS-reprogrammed glutamine metabolism sensitizes pancreatic cancer to NQO1-bioactivatable drugs G Chakrabarti, DA Boothman Cancer Research 74 (19_Supplement), 1679-1679, 2014 | 1 | 2014 |
| Compositions and methods for iron chelation P Schuber, JS AN, TA Swanson, J Helander, K Loftis, G Chakrabarti, ... US Patent App. 19/221,077, 2025 | | 2025 |
